Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 in Moderate to Severe Chronic Spontaneous Urticaria
NCT07378527Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of soficitinib in chronic spontaneous urticaria (CSU), sponsored by InnoCare Pharma. Started Feb 2026; status: recruiting.
02
Drugs
soficitinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07378527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07378527.